Literature DB >> 3760088

Simultaneous determination of perhexiline and its monohydroxy metabolites in biological fluids by gas chromatography-electron-capture detection.

R G Cooper, G Harper, A H Price, D A Evans, D Lockhart.   

Abstract

A rapid and sensitive method for the simultaneous determination of perhexiline and its cis-4-axial and trans-4-equatorial monohydroxy metabolites (M1 and M3, respectively) in human plasma, urine and bile is described. The assay utilises a single diethyl ether extraction, heptafluorobutyric acid anhydride derivatisation and separation and detection by gas chromatography-electron-capture detection. The limits of detection are 0.1 microgram/ml for perhexiline and 0.025 microgram/ml for the M1 and M3 metabolites. This method has been used in a five-day kinetic study of three healthy adult males who ingested a single 300-mg dose of perhexiline maleate. One of these volunteer subjects exhibited elevated plasma perhexiline and markedly reduced plasma and urinary M1 concentrations together with profoundly prolonged plasma and urinary M1 elimination times when compared with the other two subjects. These differences are thought to be of genetic origin. There were also obvious differences in urinary M3 concentrations which were discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3760088     DOI: 10.1016/s0378-4347(00)83596-3

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

Review 1.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

2.  Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.

Authors:  Benedetta C Sallustio; Ian S Westley; Raymond G Morris
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

3.  Studies on the metabolism of perhexiline in man.

Authors:  R G Cooper; D A Evans; A H Price
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.